Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026

Arcutis (Nasdaq: ARQT) will report first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after U.S. markets close.

Rhea-AI Summary

Arcutis (Nasdaq: ARQT) will report first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after U.S. markets close. The company will host a conference call and webcast the same day at 4:30 PM ET.

A live webcast and presentation materials will be available in the Events section of the company website, with a replay posted on Arcutis investor site after the call.

Argus Apr 16 session

-1.59% close to close Open Argus

Details

News Market Reaction – ARQT

In the Apr 16 session, ARQT declined 1.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Arcutis’s Q1 2026 financial results and a 4:30 p.m. ET conf...

Analysis

This announcement sets the timetable for Arcutis’s Q1 2026 financial results and a 4:30 p.m. ET conference call, continuing its practice of pre-announcing earnings logistics and webcast access. In context, recent insider Form 4 filings and the existence of an effective shelf registration provide additional background on potential capital and ownership dynamics. Investors often watch the actual earnings release and subsequent guidance for concrete changes to the company’s outlook.

Key Figures

Earnings release date: May 6, 2026 Conference call time: 4:30 p.m. ET Price change: 4.02% +5 more

Earnings release date

May 6, 2026

Q1 2026 financial results after U.S. market close

Conference call time

4:30 p.m. ET

Same day as Q1 2026 earnings release

Price change

4.02%

Move on day of earnings-date announcement

Current price

$25.09

Before Q1 2026 results announcement

52-week range

$11.86–$31.77

Stock trading 21.03% below 52-week high

Director sale

10,000 shares at $23.8801

Open-market sale by director Welgus on Apr 1, 2026

Director sale

39,272 shares at $25.392

Open-market sale by director Leonard on Mar 2, 2026

Insider award

77,000 options & 30,000 RSUs

Equity grants to officer Edwards on Feb 27, 2026

Previous Conferences,earnings date Reports

1 past event · Latest: Jan 22

Same Type 1 event

1. Jan 22

   Earnings date set

   24h Move

   -1.7%

   Scheduled Q4 and full-year 2025 results and investor conference appearances.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WESTLAKE VILLAGE, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its first quarter 2026 financial results and provide a business update on Wednesday, May 6, 2026 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30pm ET.

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the conference call.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available

Contacts:

Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Arcutis (ARQT) report Q1 2026 results and host the conference call?

Arcutis will report Q1 2026 results and host a call on May 6, 2026 after market close. According to the company, the webcast and call are scheduled for 4:30 PM ET with replay available on the investor website.

How can investors access the Arcutis (ARQT) May 6, 2026 earnings webcast?

Investors can access the live webcast via the company's investor website Events page. According to the company, presentation materials will be posted there and a replay will be available following the conference call for later review.

What time is the Arcutis (ARQT) conference call on May 6, 2026 and is it after market hours?

The conference call is scheduled for 4:30 PM ET on May 6, 2026, which is after U.S. market close. According to the company, the timing follows the market close to allow same-day financial reporting and a business update.

Will Arcutis (ARQT) provide presentation materials for the Q1 2026 update?

Yes. Presentation materials will be available on the company's investor site Events page at the time of the webcast. According to the company, slides accompanying the call will be posted for investor reference and included in the replay.

Is a replay of the Arcutis (ARQT) May 6, 2026 webcast available and where?

A replay will be available on the Arcutis investor website after the conference call. According to the company, the replay and related presentation materials will remain accessible for investors following the live event.

What will Arcutis (ARQT) cover in the May 6, 2026 business update?

The company will provide a business update alongside first quarter 2026 financial results during the May 6 call. According to the company, the webcast will cover financial results and related business developments for Q1 2026.